×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver

Christin L. Melton, E.L.S.
A panel of international oncology experts recently met to exchange thoughts on developments in the field of hepatocellular carcinoma (HCC), the most common form of liver cancer. They discussed screening and staging issues, treatment of advanced HCC and results of recent clinical trials.
Ghassan K. Abou-Alfa, M.D.
Can local and systemic therapies be combined to treat liver cancer?
Brielle Urciuoli
Liver cancer diagnoses have increased in the past 25 years, but researchers are hopeful that they will start to drop.
Mindy Waizer
For those with hepatitis B, taking an aspirin once a day could reduce the risk of getting liver cancer.
Mindy Waizer
A free two-day workshop will train people who want to raise awareness of liver diseases and influence public health policy to address their concerns.
Jason Harris
Overall survival (OS) was improved when patients with advanced liver cancer took Cabometyx (cabozantinib), compared to those who were given placebo. All participants previously took Nexavar (sorafenib).
 
Danielle Bucco
After nearly a decade with no new therapies, new drugs to treat liver cancer are showing great promise, according to Steven R. Alberts, M.D.
Opdivo (nivolumab) was granted FDA approval for the treatment of hepatocellular carcinoma (HCC) – regardless of PD-L1 status – for patients who have previously been treated with Nexavar (sorafenib).
 
Andrea J. Wilson
Andrea J. Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, offers advice for patients with liver cancer. Wilson started the foundation after her younger sister, Adrienne, died of liver cancer.
Jason M. Broderick
Opdivo (nivolumab) was granted a priority review designation by the Food and Drug Administration (FDA) to treat some patients with liver cancer.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable